Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

The Journal of antimicrobial chemotherapy - 1 Oct 2007

Poveda Eva, de Mendoza Carmen, Martin-Carbonero Luz, Corral Angélica, Briz Verónica, González-Lahoz Juan, Soriano Vincent

Abstract excerpt

BACKGROUND: To estimate to what extent darunavir might be effective in patients failing distinct protease inhibitors (PIs), the genotypic resistance scores recently reported for the drug were examined in a large clinical HIV-1 drug resistance database. METHODS: All clinical specimens from HIV-infected patients failing PI-based regimens referred for drug resistance testing between 1999 and 2007 to a reference...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acid Substitution
Share to Darunavir

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Viral

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Sulfonamides

Source

Identifiers

PMID: 17646201
DOI: 10.1093/jac/dkm276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.PMID 17646201Read ↗

Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil.Semantic proximity Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Prevalence of Darunavir Resistance in the United States from 2010 to 2017.Semantic proximity Read ↗

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.Semantic proximity Read ↗

Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested United States clinical samples between 2006 and 2012.Semantic proximity Read ↗

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.Semantic proximity Read ↗

Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.Semantic proximity Read ↗

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.Semantic proximity Read ↗

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.Semantic proximity Read ↗

Viremia and HIV-1 Drug Resistance Mutations Among Patients Receiving Second-Line Highly Active Antiretroviral Therapy in Chennai, Southern IndiaSemantic proximity Read ↗

Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy.Semantic proximity Read ↗

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.